This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SUMMARY: The FDA wants to look at how certain brand names affect consumer and health care providers’ perceptions about the efficacy and the medical conditions for which they’re indicated. This is just another example of how clueless the FDA is regarding patient behavior and prescription drugs. The post Dear FDA: WTF?
SUMMARY: DTC marketing is not the reason why prescription drugs cost so much. The FDA needs to study what people do when they see a DTC ad. Here are some myths around DTC marketing: 1ne: DTC ads result in patients asking for prescriptions they don’t need. DTC ads raise awareness around health conditions.
The FDA’s “accelerated approval” program expedites the evaluation process for new treatments so that patients can have access to them sooner. Between 2011 and 2018, cumulative spending on 44 FDA-approved oral targeted therapy drugs was $3.5 appeared first on World of DTC Marketing.com.
Patient behavior has changed during the pandemic as Google has shown that more are going online for health information. To portray patients, mindless people who blindly believe DTC TV ads and rush to their doctor to ask for a product are inaccurate. Prescription drugs are not the same as items found in a grocery store.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
A recent draft from the FDA provides valuable insight. Ben Locwin will discuss the potential effects of this draft, along with the pharmacological and toxicological considerations for optimizing doses of prescription drugs. What will the future hold for clinical research?
Among the 26% of respondents who talked to a health care provider about a specific prescription drug they saw advertised, 16% said they received a prescription for the advertised drug. Online research is used to evaluate new prescription drugs. What are other patients saying about it? Is TV the best channel?
The goal was simple: provide access and focused support to patients remotely while simultaneously relieving overtaxed healthcare facilities. Combined, DTx and DCTs improve patient recruitment, retention, and access, allowing researchers to pull from underserved communities, including rural populations.
SUMMARY: Per the Times, “what if consumers could calculate the benefits and risks of taking a prescription drug as easily as they can gauge the carbohydrates and calories in an Oreo cookie?” ” Drug facts boxes are needed, but the FDA disagrees. It other words it would easily communicate drug side effects to patients.
A website and TV commercials are not enough to get patients to ask for a prescription medication especially when fair balance lists side effects like cancer. DTC marketers need to understand the patient journey a lot better with specific recommendations to silence the “noise” around their medications.
(Stat News) Today, a study followed 380 patients being treated at community oncology groups across the U.S. Patients who experience financial hardship during cancer treatment are at higher risk for treatment nonadherence, poor quality of life, and worse survival. after they were diagnosed with metastatic colon cancer. population.
The US Food and Drug Administration (FDA) has granted approval to Bausch + Lomb and Novaliq’s Miebo (perfluorohexyloctane ophthalmic solution) to treat the signs and symptoms of dry eye disease (DED). It is the first and only prescription eye drop to receive FDA approval to treat DED that targets tear evaporation directly.
More and more patients demand a level of service they want with the increased costs of health insurance premiums. 1ne: The value proposition of prescription drugs still outweighs potential side effects – Wegovy’s demand quickly exceeded supply after the FDA approved once-weekly semaglutide injections.
The FDA on Tuesday approved Aadi Bioscience’s first drug and the first treatment approved specifically for patients with an ultra-rare and aggressive form of sarcoma that occurs mostly in women. Rapamycin was approved in 1999 and it’s also worth noting their Phase II was a tiny patient population.
GOOD MORNING: The FDA is taking a scientific approach to evaluating direct-to-consumer (DTC) drug advertising, focusing on measuring consumer perceptions of the information presented in ads. ” So, are we supposed to believe that better images in DTC ads lead to patients asking for an Rx? ” Uh…no. ” Uh…no.
QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. Patients should be scared. We need a 21st-century approach that puts patient safety first. The adulterated product was found to have caused nine patient deaths and 574 serious adverse events (SAEs). In other words, money over safety.
OPENING: American cancer patients spent more than $21 billion on their care in 2019. billion and patient time costs of $4.87 Some cancer patients may face out-of-pocket costs of nearly $12,000 a year for one drug. Many cancer patients without adequate insurance have only the starkest choice: your money or your life.
In a highly regulated industry, choosing the right keywords can determine whether your ads reach healthcare professionals, patients, or caregivers effectively. Understanding how patients and healthcare professionals search for medical information is key. Januvia prescription cost) and non-branded (e.g., A mix of branded (e.g.,
Most patients completely trusted their physicians “to put their needs above all other considerations” (69%). According to Accenture, “the pharma industry has ‘earned’ some modest gains in trust from patients due to vaccine development. Even patients will still line up if a prescription drug shows promise.
Patients want quick fixes, and the idea of losing some weight because of a new drug is enticing to them. In response, the company has been providing six-month waivers to some insured patients that will cap the drug’s out-of-pocket costs at $25 a month, though the long-term picture of coverage is still in flux. Click to Tweet.
With millions of healthcare professionals (HCPs) and patients turning to Google for medical information, paid search ads present a huge opportunity for pharma brands to boost engagement and conversions. Strict ad copy guidelines , including FDA-mandated fair balance requirements. However, the landscape isnt simple.
In this article, well dive into key pharma digital marketing strategies that can help pharma brands connect with healthcare professionals (HCPs), patients, and stakeholders effectively. Improve patient engagement with valuable content and resources. Improve patient engagement with valuable content and resources.
The cost of Humira, which is injected via syringe, was more than $72,000 a year on prescription drug websites this week and is not expected to come down until at least 2023. AbbVie significantly inflated prices over the past two decades for patients in the U.S. Richard Gonzalez, C.E.O. So how do people who work for AbbVie feel?
The US Food and Drug Administration (FDA) has granted priority review for Takeda and HUTCHMED’s new drug application (NDA) for fruquintinib. This 691-patient study was conducted in Europe, the US, Japan and Australia. The FDA has now assigned a prescription drug user fee act action date of 23 November 2023 for the NDA.
This guide breaks down best practices for PPC campaign optimization , helping pharma marketers reach HCPs and patients without wasting ad spend. Pay-per-click (PPC) advertising allows brands to reach healthcare professionals (HCPs) and patients when they are actively searching for treatment options, drug information, or medical education.
A new feature—a sensor that monitors changes in the heart rate for irregularities that can lead to strokes and heart failure—has just been approved by America’s Food and Drug Administration (FDA). The FDA’s stamp of approval for the Fitbit sensor is a big deal. Google is also giving health records another whirl.
Visting my doctor for my annual physical, I noticed huge LCD screens in each exam room with rotating ads for everything from prescription drugs to vitamins. Second, do people trust the FDA? For them, it’s about two things: relevant data that can be corroborated and improvements in patient outcomes.
The FDA has issued a complete response letter (CRL) to Spectrum Pharma for poziotinib, its pan HER2 inhibitor for a form of lung cancer, according to South Korea’s Hanmi Pharma, which originally developed the drug. The post FDA rejects Spectrum’s lung cancer drug poziotinib appeared first on.
The US Food and Drug Administration (FDA) has granted approval for Amylyx Pharmaceuticals’ Relyvrio (sodium phenylbutyrate and taurursodiol) to treat adult patients with amyotrophic lateral sclerosis (ALS). The FDA approval is based on findings from the multicentre Phase II CENTAUR clinical trial that enrolled 137 ALS patients.
UK-based pharmaceutical giant GSK has announced that the US Food and Drug Administration (FDA) has extended the review period of its new drug application (NDA) for the rare bone cancer drug momelotinib by three months. The FDA’s review will take into account data from the Phase III MOMENTUM trial (NCT04173494).
In todays competitive market, where digital strategies and patient-centric approaches are essential, having an expert partner is more critical than ever. A pharmaceutical marketing company does more than run adsit builds connections between your brand, healthcare providers (HCPs), and patients.
The US Food and Drug Administration (FDA) has pushed quizartinib’s Prescription Drug User Fee Act (PDUFA) date in newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) for the review of updates of Risk Evaluation and Mitigation Strategies (REMS) included in the application. The median OS in patients on quizartinib was 31.9
The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a new drug application (NDA) for its investigational single-tablet combination therapy of macitentan 10mg and tadalafil 40mg (M/T STCT) to the US Food and Drug Administration (FDA), to treat pulmonary arterial hypertension (PAH).
I continue to believe that there are very good people who care about patients working within pharma but it’s hard to understand how anyone who works for AbbVie can feel good about their employer. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S.
Pfizer is still waiting for the green light to complete an acquisition of digital health company ResApp, a deal that looks even better now that its smartphone app for people with obstructive sleep apnoea (OSA) has been approved by the FDA. The post ResApp bags FDA okay for sleep apnoea app, after Pfizer takeover bid appeared first on.
Patient organisations have been celebrating the FDA approval yesterday of Amylyx’ amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after not one but two advisory committee meetings that arrived at different conclusions about the drug. An oral version of edaravone was cleared this year.
Pharma companies are leveraging AI to: Personalize HCP and patient outreach Optimize digital ad placements Generate high-volume content at scale Predict prescription patterns Analyze social listening data for insights These applications offer the promise of real-time engagement, data-driven decisions, and measurable ROI.
AGEPHA Pharma has received approval from the US Food and Drug Administration (FDA) for LODOCO (colchicine, 0.5 The regulatory approval was based on the findings obtained from a double-blind, multinational, placebo-controlled, randomised clinical trial conducted in 5,522 chronic coronary disease patients.
Jazz Pharmaceuticals has introduced a new prescription medication for patients with sleep apnea/narcolepsy that “helped adults get up to 9 hours of improved wakefulness in clinical studies at 12 weeks” and they’re using a flying pig on their DTC. billion by 2026. This DTC is an embaressment.
The US Food and Drug Administration (FDA) has accepted the supplemental biologics licence application submitted by Bristol Myers Squibb for Reblozyl (luspatercept-aamt) as a first-line treatment of anaemia in adults with lower-risk myelodysplastic syndromes (MDS).
By embracing patient-centric approaches, leveraging digital tools, and staying ahead of trends. The rise of generic drug competitors, stringent regulatory environments, and increasingly empowered patients mean one-size-fits-all approaches no longer work. They are key decision-makers influencing prescription trends.
The new Food and Drug Administration (FDA)’s Decentralized Clinical Trial Draft Guidance issued May 1 st has started to outline guidelines for increased oversight and planning while simultaneously supporting broader DCT adoption. The guidance document is short at 19 pages, and by design not prescriptive.
Pharma websites provide the prescription that can help people overcome health problems but too often, they ignore the patient’s responsibility to lose weight and exercise. The FDA should require every pharma product website to devote part of its content to prevention and the importance of exercise.
Marketing in pharma has undergone a radical shift, propelled by digital transformation, patient-centric demands, and evolving regulatory landscapes. Pharmaceutical brands like Dupixent, Keytruda, and Ozempic are leading the way with creative digital campaigns that blend patient education with dynamic storytelling.
Introduction In an era dominated by digital marketing, traditional advertising remains a vital tool for pharma companies to connect with healthcare professionals (HCPs) and patients alike. Unlike digital ads that can feel fleeting, traditional campaigns offer lasting impressions, cementing brand authority and patient trust.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content